Company News

Quarterly Report – Period To 30 September 2023

October 17, 2023
Orthocell has today published its Quarterly Report for the period ended 30 September 2023. Highlights for this Quarter include:
  • Increased total revenue up 71% from Q1 FY23  
  • Second US distributor now actively marketing and selling Striate+™ as a private labelled product
  • Nerve repair study to support US regulatory clearance for Remplir™commenced and on track for completion 1Q CY2024
  • Pivotal tendon repair study on track for data read out in 4Q CY2023
  • Strong balance sheet with $22.3m cash at bank at the end of the quarter
Orthocell Managing Director, Paul Anderson, said: “We are very pleased with the performance of our distribution partners and the continued quarterly increase in product revenue. Successful product launches of Remplir™ in Australia and Striate+™ in the USA and Europe by our partners, has seen increases in surgeon engagement and broad uptake of our products, ensuring we are well positioned to continue to gain commercial traction and revenue growth.” Click here to read today’s ASX release.